Cadrenal Therapeutics, Inc. Common Stock
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patien…
Biotechnology
US, Ponte Vedra [HQ]
Risk Factors
By Management
Not Available
No Risk Factor available yet. You can request "Risk Factors" through an email.